
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics is making significant strides in the development of its peptide-based therapeutics, particularly with rusfertide and icotrokinra. They have addressed potential safety issues with rusfertide and have a strong pipeline with several potential catalysts on the horizon, including potential partnerships for their obesity drugs. With a strong cash position and potential peak market opportunities exceeding $10 billion, PTGX is well-positioned for long-term success.
Bears say
Protagonist Therapeutics is experiencing a positive launch for Icotyde, with strong prescriber growth and commercial coverage. However, their other pipeline candidates, such as PN-881 for obesity, are still in the early stages of development and their success is uncertain. Additionally, the Ph2 trial design for their IL-17 program will be a key factor in determining the potential of PN-881, and investors should closely monitor its progress. Protagonist Therapeutics has a promising pipeline but also faces significant risks and uncertainties, leading to a negative outlook.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares